Results 111 to 120 of about 3,148 (231)

Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy.

Journal of Lipid Research, 1994
To determine the acute and long-term effects of low density lipoprotein (LDL) reduction on cholesterol biosynthesis, we studied changes in the cholesterol precursors mevalonic acid (MVA) and lathosterol in patients with heterozygous familial ...
M Pfohl, R P Naoumova, C Klass, W Knisel, B Jakober, T Risler, G R Thompson   +6 more
doaj  

Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease [PDF]

, 2013
Josef Leebmann, E. Roeseler, Ulrich Julius, Franz Heigl, Ralf Spitthoever, Dennis Heutling, Paul Breitenberger, Winfried Maerz, Walter Lehmacher, Andreas Heibges, Reinhard Klingel   +10 more
openalex   +1 more source

Comparison of plasma separation using centrifugation or filtration for MONET lipoprotein apheresis in patients with cardiovascular disease and severe dyslipidemia. [PDF]

Ther Apher Dial, 2022
Waitz G, Atiye S, Gauly A, Prophet H.
europepmc   +1 more source

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis [PDF]

, 2013
Mary P. McGowan
openalex   +1 more source

The development of lipoprotein apheresis in Saxony in the last years [PDF]

, 2022
Solveig Kuss, Ulrike Schatz, Sergey Tselmin, Sabine Fischer, Ulrich Julius   +4 more
openalex   +1 more source

Annual Sickle Cell & Thalassaemia Conference (ASCAT) ‐ October 2023

HemaSphere, Volume 8, Issue S3, December 2024.
wiley   +1 more source

Intensive Combination LDL-Lowering Therapy in a Patient With Homozygous Familial Hypercholesterolemia

JACC: Case Reports
We present a young boy with a diagnosis of homozygous familial hypercholesterolemia who presented with statin and ezetimibe resistance. The patient received lipoprotein apheresis at 6 years of age.
Hayato Tada, MD, Hirofumi Okada, MD, Masa-aki Kawashiri, MD, Masayuki Takamura, MD   +3 more
doaj  

Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function. [PDF]

Ther Apher Dial, 2022
Muso E, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, Saito T, Mune M, Sugiyama S, Iino Y, Hirano T, Hattori M, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Oda H, Mori K, Kimura H, Ito O, Nishiyama A, Maruyama S, Inagi R, Fujimoto S, Tsukamoto T, Suzuki Y, Honda H, Babazono T, Tsuruya K, Yuzawa Y.   +31 more
europepmc   +1 more source

Switching from lipoprotein apheresis to evolocumab in FH siblings on hemodialysis: case reports and discussion. [PDF]

CEN Case Rep, 2021
Ishii T, Ogura M, Nakamori H, Hori M, Harada-Shiba M, Tamura K, Oyama K.   +6 more
europepmc   +1 more source

Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease [PDF]

, 2015
Franz Heigl, R Hettich, Norbert Lotz, Harduin Reeg, Tobias Pflederer, D Osterkorn, K. Osterkorn, Reinhard Klingel   +7 more
openalex   +1 more source